Onyx-015 clinical trial

Author: bygh

August undefined, 2024

Web1 de ago. de 2000 · Encouraging results are reported in Phase 2 clinical trials of the virus Onyx-015 in treatment of head and neck cancers; treatment is based on Dr Frank McCormick's insight that Onyx-015 is ... WebFunctional imaging, such as positron emission tomography (PET) scans, may help distinguish clinical responses from progressive disease following treatment with oncolytic viruses. Onyx-015 may benefit patients with refractory colorectal cancer and additional studies that include PET scans to assess clinical response are warranted.

Oncolytic virotherapy: basic principles, recent advances and future ...

Web6 de mar. de 2001 · A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent … Web25 de jan. de 2002 · Based on the encouraging preclinical experience with ONYX-015, clinical trials have been initiated in patients with squamous carcinomas of the head and neck (HNSCC), and pancreatic cancer. grant thornton moncton

ONYX-015 With Cisplatin and Fluorouracil in Treating …

Web1 de mar. de 2000 · A clinical trial of cisplatin/5-fluorouracil combined with Onyx-015 has recently been completed in patients with recurrent head and neck cancer, and the results are very promising . In summary, we have shown that intratumoral injection of the E1B-attenuated replicating adenovirus Onyx-015 is feasible and safe with very limited toxicity. WebLarry Junck, in Handbook of Clinical Neurology, 2012. Phase II trials. A phase II trial generally uses as its dose the MTD from a phase I trial. Because the number of patients treated at this dose in the previous phase I trial may be as few as 6, investigators in a phase II trial may need to consider decreasing the dose, if they observe excessive toxicity, or … Web1 de jul. de 2003 · In 1996, ONYX-015 entered clinical trials for treatment of. ca ncer of the head and neck. This indication was chosen because. tumors are readily accessible to dir ect injection and also for biopsy. chipotle bg ohio

JPM Free Full-Text Feasibility of Outpatient Transradial Prostatic ...

Clinical research results with dl1520 (Onyx-015), a replication ...

Web29 de abr. de 2004 · Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may … Web1 de fev. de 2003 · The ONYX-015 virus itself was well tolerated, as was its combination with gemcitabine. This is consistent with a favorable safety profile of ONYX-015 alone … grant thornton model ifrs accountsWebBy the combination of 5Fu and cisplatin in the phase II clinical trial, ONYX-015 had reached 63% therapeutic effect (20/30), including complete response in patients with the recurrent squamous cell cancer of the head and neck in 2000. 76 Based on ONYX-015, the term virotherapy was nominated by Kirn in 2001. 77 However, the ONYX-015 alone … grant thornton montreal

"Web15 de nov. de 2000 · Abstract. ONYX-015 is an E1B-55kDa gene-deleted adenovirus engineered to selectively replicate in and lyse p53-deficient cancer cells. To evaluate the selectivity of ONYX-015 replication and cytopathic effects for the first time in humans, we carried out a Phase II clinical testing of intratumoral and peritumoral ONYX-015 injection … " - Onyx-015 clinical trial

Onyx-015 clinical trial

Clinical utility of recombinant adenoviral human p53 gene therapy ...

Web8 de abr. de 2024 · Published clinical trials provide data of the safety and some signs of oncolytic activity of conditionally-replicative adenoviruses in patients with pancreatic cancer. ... The first study of ONYX-015 in 2001 used doses between 2 × 10 9 and 2 × 10 12 viral particles and the maximum tolerated dose was not reached. WebONYX-015 is an attenuated chimeric human group C adenovirus, which preferentially replicates in and lyses tumor cells that are p53 negative. The purpose of this phase I, …

Did you know?

Web6 de mar. de 2001 · Results from clinical trials with dl1520 (Onyx-015) Toxicity. The toxicity findings from trials of dl1520 (Onyx-015) are outlined in Tables 1, 2 and 3. WebOnyx-015 clinical trials have been conducted in several types of cancer, and a Phase I trial for malignant glioma was reported in 2004. 18 In this trial, Onyx-015 was injected …

WebOther Phase I/II trials showed that patients with advanced sarcomas, hepatobiliary tumors, and malignant gliomas could tolerate ONYX 015, alone or with other chemotherapy, well and safely. 62–64 They also provided some evidence of antitumor activity for ONYX 015. However, the clinical effect of ONYX 015 has varied greatly, and there are still ... WebIf Onyx-015 infects a normal cell, with a functioning p53 gene, it will be prevented from multiplying by the action of the p53 transcription factor. However, if Onyx-015 infects a …

WebONYX-015 was infused intravenously at escalating doses of 2 x 10(10) to 2 x 10(13) particles via weekly infusion within 21-day cycles in 10 patients with advanced carcinoma … Web13 de jan. de 2005 · ONYX-015, which does not express a therapeutic or a fail-safe gene, has been administered to over 250 cancer patients in roughly 15 clinical trials in a …

Web1 de nov. de 2004 · ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 10 7 plaque-forming units (pfu) to 10 10 pfu into a total of 10 sites within the …

WebOnyx-015 clinical trials have been conducted in several types of cancer, and a Phase I trial for malignant glioma was reported in 2004. 18 In this trial, Onyx-015 was injected into the brain that surrounded a surgically resected glioma. grant thornton montpellierWeb21 de set. de 2016 · ONYX-015 (dl1520) is a replication-selective adenovirus. 34 Efficient adenovirus replication is dependent on the expression of proteins that inactivate p53. … chipotle bg kyWeb11 de abr. de 2024 · Robust results from clinical trials using OV as a treatment congruously suggested ... was deleted in many oncolytic Ads such as H101 and ONYX-015. 87 E1B 55kD-ablated adenoviruses are more ... chipotle billings mtWeb1 de dez. de 2003 · ONYX-015 is an attractive therapeutic adenovirus for cancer because it can selectively replicate in tumor cells and kill them. To date, clinical trials of this adenovirus have demonstrated marked ... grant thornton moroccoWeb1 de jul. de 2003 · In 1996, ONYX-015 entered clinical trials for treatment of. ca ncer of the head and neck. This indication was chosen because. tumors are readily accessible to dir … chipotle billingsWeb1 de jan. de 2009 · In 1996, ONYX-015 was the first oncolytic virus to enter human clinical trials . The virus has demonstrated a remarkable safety profile, independent of the route of administration. The maximum tolerated dose has not been reached after intratumoral, hepatic artery, intraperitoneal, or systemic administration of the virus ( 8 , 10 – 12 ). chipotle birthday clubWebIn 1996, ONYX-015 entered clinical trials for treatment of cancer of the head and neck. This indication was chosen because tumors are readily accessible to direct injection and also for biopsy. It was considered important to determine whether ONYX-015 indeed replicates in tumor cells in humans, and this protocol allowed this question to be ... grant thornton mozambique